What are the main therapeutic effects and mechanisms of action of Lazertinib?

Lazertinib (Lazertinib) is a new third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI< /span>), mainly used to treat patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). Its remarkable therapeutic effect has made it an important breakthrough in the field of targeted treatment of lung cancer in recent years. Lanzertinib effectively blocks the signal transduction of tumor cells and inhibits tumor growth and spread by highly selectively inhibiting EGFR sensitive mutations and drug-resistant mutations (such as the T790M mutation).

The main mechanism of action of Lanzertinib is through competitive binding to the ATP binding site on the EGFR tyrosine kinase domain , inhibiting its enzymatic activity, thereby blocking downstream signaling pathways, such as the RAS/RAF/MEK/ERK and PI3K/AKT pathways. These pathways play key roles in tumor cell proliferation, survival, and migration. Lanzertinib can not only effectively inhibit common sensitive mutations, but also overcome the drug resistance problem caused by the T790M mutation, thus extending the progression-free survival of patients.

Clinical trial data show that lanzutinib has shown good efficacy in the treatment of EGFR T790Mpositive NSCLC patients. After patients took lanzetinib, the tumor response rate was significantly improved and the progression-free survival was significantly prolonged. In addition, lanzetinib has good penetration ability in the central nervous system (CNS) and also shows positive therapeutic effects on patients with brain metastases. This feature makes it more advantageous in clinical application.

In general, Lanzertinib has significantly improved the prognosis of patients with non-small cell lung cancer by precisely targeting EGFR mutations and drug-resistant mutations. Its good efficacy and relatively low side effects provide new treatment options for lung cancer patients. In the future, with the accumulation of more clinical data, lanzertinib is expected to play an important role in more clinical scenarios and further promote the development of targeted therapy for lung cancer.

Reference materials:https://www.drugs.com/donanemab.html